Lenzing AG

Lenzing Aktiengesellschaft produces and markets wood-based cellulosic fibers for the textile and nonwoven sectors in Austria, rest of Europe, Asia, the Americas, and internationally. The company operates through Division Fiber, Division Pulp, and Others segments. It offers lyocell fibers for applications in sportswear, home textiles, and mattresses, as well as hygiene articles such as wet wipes and baby wipes; modal fibers; viscose fibers for use in clothing fabrics, wipes, tampons, and wound dressings; and filament yarns under the LENZING, TENCEL, VEOCEL, and LENZING ECOVERO brand names. The company also provides biorefinery products comprising acetic acid biobased, furfural biobased, magnesium lignosulphonate biobased, soda ash, sodium sulphate, and xylose. It also operates in the field of mechanical and plant engineering; engages in the training and personnel development activities; and provides engineering services. The company was formerly known as Chemiefaser Lenzing AG and changed its name to Lenzing Aktiengesellschaft in 1984. Lenzing Aktiengesellschaft was founded in 1892 and is headquartered in Lenzing, Austria.

Lenzing AG trades as LNZNF on OTC. The company is classified in Basic Materials / Chemicals and reports in USD.

The current profile places the business in Chemicals. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $2.60B of revenue and -$171.97M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Lenzing AG can be compared against peers such as ALPEK, S.A.B. de C.V., Borregaard ASA Unsponsored ADR, Canfor Corporation, D&L Industries, Inc., Orbia Advance Corporation, S.A.B. de C.V., OCI N.V..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $1.10B, beta of 1.01, and return on equity of -35.1%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

LNZNF currently shows total debt of $2.65B and beta of 1.01. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.lenzing.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.